Back |
home / stock / immx / immx message board
Subject | By | Source | When |
---|---|---|---|
Didnt happen, back down showing 2.20 area, reload | harry crumb | investorshub | 01/08/2023 7:44:23 PM |
Then it crashed to $1.75. | Laster | investorshub | 01/06/2023 1:51:49 PM |
$,3.07 pre on this news Immix Biopharma | subslover | investorshub | 01/06/2023 1:06:47 PM |
Stock just hit $2.40. | Laster | investorshub | 12/30/2022 5:15:10 PM |
Break $2,40 and then $2.50 and it runs | Laster | investorshub | 12/30/2022 1:54:40 PM |
word is.. very good.. | vegasandre | investorshub | 12/21/2022 7:34:20 PM |
Shorts will take this down to the 1.20s, | harry crumb | investorshub | 12/15/2022 12:41:08 PM |
znewcar1: $IMMX 23% v59,6M C1.80 f13,9M H2.52 ML87 LL.68 | znewcar1 | investorshangout | 12/15/2022 12:59:08 AM |
so float is under 6 mill . outstanding | vegasandre | investorshub | 12/14/2022 4:36:11 PM |
super low float... | vegasandre | investorshub | 12/14/2022 3:33:35 PM |
I agree...it never holds. I lost big-time on | Pedro2004 | investorshub | 12/14/2022 2:45:03 PM |
It wont hold. Never does. Timberrrrr | Jess070283 | investorshub | 12/14/2022 2:35:23 PM |
Immix Biopharma in-licenses NXC-201, BCMA-targeted Next-Generation CAR-T Therapy | subslover | investorshub | 12/14/2022 2:19:27 PM |
ImmixBio Releases and Ships Scaled-Up GMP Batches of | subslover | investorshub | 12/12/2022 2:38:19 PM |
znewcar1: IMMX 29% v42,4M c2.39 f13,8M H2.7599 gapNtrap rip to HOD then slide under of YL1.77 20dma@ | znewcar1 | investorshangout | 06/02/2022 10:55:36 PM |
znewcar1: IMMX 30% v111M c2.12 f13,8M H2.87 mostly sideways since gap up Bear trap on the 2nd BO>2.8 | znewcar1 | investorshangout | 05/20/2022 11:11:38 PM |
znewcar1: IMMX 25% v1,7M c1.63 f13,8M H1.6881 ML1.25 | znewcar1 | investorshangout | 05/20/2022 2:47:26 AM |
News, Short Squeeze, Breakout and More Instantly...
Immix Biopharma Inc. Company Name:
IMMX Stock Symbol:
NASDAQ Market:
European Orphan Drug Designation (“ODD”) qualifies NXC-201 for: 10 years of market exclusivity once authorized in the EU Access to the EU centralized authorization procedure Reduced fees for: EU protocol assistance, marketing authorization applications, inspections bef...
Scheduling U.S. site initiation visits April and May 2024 On track to dose relapsed/refractory AL Amyloidosis patients with CAR-T NXC-201 at New York City lead site and other leading U.S. sites mid-2024 No change in patient enrollment timing LOS ANGELES, April 18, 2024 (GLOBE NEWSWI...
Updated clinical data for next-generation CAR-T NXC-201 in relapsed/refractory AL amyloidosis will be presented in Baltimore May 7-11, 2024 LOS ...